high-dose-lung-delivery
(2)
Noel Greenberger
Noel Greenberger is the CEO of Nob Hill Therapeutics, an Albuquerque-based respiratory company building DryNeb, a dry powder nebulizer that pushes high therapeutic doses deep into the lungs regardless of a patient's breathing capacity. A Wharton MBA and Northwestern-trained industrial engineer, he spent years commercializing respiratory medicines at Sandoz, ran commercial strategy at Vertice Pharma, and consulted at McKinsey and ZS Associates before taking the helm of Nob Hill in 2022. Under his watch the company won a $1.73M HHS Phase II grant and closed a $3M Series A in 2024.
Nob Hill Therapeutics
Nob Hill Therapeutics is an Albuquerque, New Mexico respiratory healthcare company re-envisioning inhalation medicines. Its patented DryNeb dry powder nebulizer is designed to deliver high doses of medicine directly to the lungs while a patient breathes normally, combining the strengths of dry powder inhalers and liquid nebulizers. Spun out of VIC Technology Venture Development and based on the Lovelace Respiratory Research Institute campus, the company is targeting hard-to-treat lung diseases such as lower respiratory tract infections, lung fungal infections and lung cancer.